HONG KONG -- (Marketwire) -- 02/06/12 -- Today, www.BollingerReport.com introduced featured coverage of Sanofi SA (ADR) (NYSE: SNY) and Endo Pharmaceuticals (NASDAQ: ENDP). Full research reports are available to readers at: www.BollingerReport.com/index.php'sm1=SNY&sm2=ENDP.
Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experienced in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.
Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.
Bollinger Report screened and selected Sanofi SA (ADR) for its current position within the healthcare industry. Sanofi, formerly Sanofi-Aventis, is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. A copy of this report featuring Sanofi SA (ADR) (NYSE: SNY) is available at: www.BollingerReport.com/index.php'sm1=SNY.
Bollinger Report is featuring Endo Pharmaceuticals for its changing role within the healthcare industry. Endo Pharmaceuticals Holdings Inc. (Endo) is a specialty healthcare solutions company focused on branded products and generics, and devices and services. The Company has a portfolio of branded pharmaceuticals, which includes brand names such as Lidoderm, Opana ER and Opana, Percocet, Frova, Voltaren Gel, Vantas, Valstar, and Supprelin LA. To download researches and analysis on Endo Pharmaceuticals (NASDAQ: ENDP) we welcome investors to visit: www.BollingerReport.com/index.php'sm2=ENDP.
About Bollinger Report
Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.
Contact:
Martin Schwartz
Email Contact
www.BollingerReport.com
